• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION SYNERGY; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION SYNERGY; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number 10622
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Angina (1710); Reocclusion (1985); No Code Available (3191); Restenosis (4576)
Event Date 09/09/2020
Event Type  Injury  
Manufacturer Narrative
(b)(6).
 
Event Description
(b)(6) study.It was reported that the subject experienced unstable angina.In (b)(6) 2019, the subject was referred for cardiac catherization and four days after, the index procedure was performed.Target lesion #1 was located in the mid left anterior descending (lad) artery with 80% stenosis and was 25 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 2.25 x 28 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.Target lesion #2 was located in the left main coronary artery (lmca) with 80% stenosis and was 29 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 3.00 x 32 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.The following day abnormal troponin increased after operation.Five days after, the patient was discharged on aspirin and ticagrelor.In (b)(6) 2020, the subject presented with symptoms of angina pectoris and was hospitalized on the same day for further evaluation and treatment.The subject was diagnosed with the unstable angina pectoris.Two days later, the subject was referred for coronary angiography which revealed lad (target vessel) with 90% proximal stenosis which was treated with percutaneous coronary intervention (pci) (target vessel revascularization/tvr).Post intervention, residual stenosis was 0%.Three days later, the event was considered recovered/resolved and the subject was discharged on the same day.
 
Event Description
Same case as pr id# (b)(6).Synergy china registry study.It was reported that unstable angina occurred.In (b)(6) 2019, the patient was referred for cardiac catherization and four days after, index procedure was performed.The target lesion #1 was located in the mid left anterior descending (lad) artery with 80% stenosis and was 25 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 2.25 x 28 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.The target lesion #2 was located in the left main coronary artery (lmca) with 80% stenosis and was 29 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 3.00 x 32 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.The following day abnormal troponin increased after operation.Five days after, the patient was discharged on aspirin and ticagrelor.In (b)(6) 2020, the patient presented with symptoms of angina pectoris and was hospitalized on the same day for further evaluation and treatment.The patient was diagnosed with the unstable angina pectoris.Two days later, the subject was referred for coronary angiography which revealed lad with 90% proximal stenosis was treated with pci (tvr).Post intervention, residual stenosis was 0%.Three days later, the event was considered recovered/resolved and the patient was discharged on the same day.It was further reported that target lesion #1 reference diameter was 2.25mm.Target lesion #2 was located in the lmca extending up to proximal lad with 60% stenosis.
 
Manufacturer Narrative
E1 initial reporter address 1: (b)(6).
 
Manufacturer Narrative
E1: initial reporter address 1: (b)(6).
 
Event Description
Same case as pr id# (b)(4).Synergy china registry.It was reported that the subject experienced unstable angina.In (b)(6) 2019, the subject was referred for cardiac catheterization and four days after, the index procedure was performed.Target lesion #1 was located in the mid left anterior descending (lad) artery with 80% stenosis and was 25 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 2.25 x 28 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.Target lesion #2 was located in the left main coronary artery (lmca) with 80% stenosis and was 29 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 3.00 x 32 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.The following day abnormal troponin increased after operation.Five days after, the patient was discharged on aspirin and ticagrelor.In (b)(6) 2020, the subject presented with symptoms of angina pectoris and was hospitalized on the same day for further evaluation and treatment.The subject was diagnosed with the unstable angina pectoris.Two days later, the subject was referred for coronary angiography which revealed lad (target vessel) with 90% proximal stenosis which was treated with percutaneous coronary intervention (pci) (target vessel revascularization/tvr).Post intervention, residual stenosis was 0%.Three days later, the event was considered recovered/resolved and the subject was discharged on the same day.It was further reported that target lesion #1 reference diameter was 2.25mm.Target lesion #2 was located in the lmca extending up to proximal lad with 60% stenosis.It was further reported that in february 2021, the subject was diagnosed with unstable angina pectoris.The subject was hospitalized for further evaluation and treatment.No other action was taken to treat the event.Six days later, the subject was discharged on aspirin and ticagrelor.At the time of reporting, the event was recovering and resolving.The physician considers the study device is unlikely related to the event.
 
Event Description
Same case as pr id# (b)(4).Synergy china registry it was reported that the subject experienced unstable angina.In october 2019, the subject was referred for cardiac catheterization and four days after, the index procedure was performed.Target lesion #1 was located in the mid left anterior descending (lad) artery with 80% stenosis and was 25 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 2.25 x 28 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.Target lesion #2 was located in the left main coronary artery (lmca) with 80% stenosis and was 29 mm long, with a reference vessel diameter of 3.0 mm.The target lesion was treated with pre-dilatation and placement of a 3.00 x 32 mm synergy stent system.Following post-dilatation, the residual stenosis was 0%.The following day abnormal troponin increased after operation.Five days after, the patient was discharged on aspirin and ticagrelor.In (b)(6) 2020, the subject presented with symptoms of angina pectoris and was hospitalized on the same day for further evaluation and treatment.The subject was diagnosed with the unstable angina pectoris.Two days later, the subject was referred for coronary angiography which revealed lad (target vessel) with 90% proximal stenosis which was treated with percutaneous coronary intervention (pci) (target vessel revascularization/tvr).Post intervention, residual stenosis was 0%.Three days later, the event was considered recovered/resolved and the subject was discharged on the same day.It was further reported that target lesion #1 reference diameter was 2.25mm.Target lesion #2 was located in the lmca extending up to proximal lad with 60% stenosis.It was further reported that in (b)(6) 2021, the subject was diagnosed with unstable angina pectoris.The subject was hospitalized for further evaluation and treatment.No other action was taken to treat the event.Six days later, the subject was discharged on aspirin and ticagrelor.At the time of reporting, the event was recovering and resolving.The physician considers the study device is unlikely related to the event.It was further reported that in (b)(6) 2021, the subject was diagnosed with unstable angina pectoris and was hospitalized for further evaluation and treatment.A week and three days later, the subject was referred for coronary angiography which revealed 80% stenosis in mid lad extending up to distal lad which had previously placed study device.Medication was given to treat the event and coronary bypass graft (cabg) surgery was performed (tvr).Post intervention, residual stenosis was unknown.At the time of reporting, the event was recovering and resolving.Two weeks and three days later, the subject was discharged.The physician considers the study device is unlikely related to the event.
 
Manufacturer Narrative
B5.Describe event or problem- updated.D4: model number updated.D4: lot number - corrected from 23602806 to 23602808.D4: expiration date updated to 09/29/2020.D4: unique identifier (udi) # updated.E1 initial reporter address 1: (b)(6).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
two scimed place
maple grove MN 55311
MDR Report Key10684593
MDR Text Key211507830
Report Number2134265-2020-14077
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup,Followup,Followup
Report Date 07/20/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date09/29/2020
Device Model Number10622
Device Catalogue Number10622
Device Lot Number0023602808
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 09/30/2020
Initial Date FDA Received10/15/2020
Supplement Dates Manufacturer Received10/20/2020
05/31/2021
06/30/2021
Supplement Dates FDA Received11/12/2020
06/22/2021
07/20/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age49 YR
-
-